Amivantamab Plus Lazertinib Improves PFS Over Osimertinib in EGFRm NSCLC
Topline results from MARIPOSA reveal a survival advantage with amivantamab plus lazertinib vs osimertinib in patients with EGFR-mutant non–small cell lung cancer. Additional follow-up is planned.
LINKER-MM1: Efficacy and Safety Data of Linvoseltamab 200 mg in MM
Joshua Richter, MD, evaluates the efficacy and safety data of linvoseltamab for the treatment of patients with multiple myeloma.
FDA Fast Tracks IDE161 for BRCA1/2-Mutated HR+/HER2- Breast Cancer
IDE161 now has 2 fast track designations from the FDA for patients with breast cancer and ovarian cancer. The agent continues to be evaluated in a first-in-human, phase 1 study for patients with advanced solid tumors.
GC012F CAR T Shows 100% Complete Response Rate in Multiple Myeloma
Researchers presented updated results from longer-term follow-up studies of GC012F for newly-diagnosed multiple myeloma treatment at the International Myeloma Society Annual Meeting.
Methods and Design of Phase 1/2 Glofitamab Study in LBCL
Cyrus M. Khan, MD, discusses the phase 1/2 trial of glofitamab for use as a treatment option for patients with relapsed/refractory large B-cell lymphoma.
Positive MRD Outcomes Seen With Isa-KRd in Newly Diagnosed, High-Risk Multiple Myeloma
The Isa-KRd combination in the GMMG-CONCEPT trial yielded high MRD negativity rates among patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.
In Advanced Prostate Cancer, a String of Modest Gains Are Changing Patient Care
Robert Dreicer, MD, MS, MACP, FASCO, acknowledges that there have been substantial developments in therapies and strategies for treating prostate cancer, leading to heightened expectations of breakthroughs in the field.
Doctors’ Debate: Frontline Targeted Therapies Inform Treatment Decisions in HCC
Richard S. Finn, MD, and R. Kate (Katie) Kelley, MD, emerged in a discussion about the factors that inform treatment decisions for patients with hepatocellular carcinoma during the International Liver Cancer Association Annual Conference 2023.
CAN-2409 Combination Elicits Encouraging Survival Results in NSCLC
Treatment with CAN-2409 produced promising survival data and continues to show a favorable safety and tolerability profile for the treatment of non-resectable, stage III/IV non–small cell lung cancer.
Dosing of TARA-002 in NMIBC Commences in Phase 1b/2 Study
The ADVANCED-2 trial plans to build onto the early antitumor and safety data seen with TARA-002 that were presented this year for patients with non-muscle invasive bladder cancer.
FDA Approves Bosutinib for Pediatric Patients With CP-CML
Bosutinib has a new indication in leukemia as a well as a newly-approved formulation.
Choosing the Optimal First-Line Regimen for Patients With Advanced HCC
In an interview with Targeted Oncology, Richard S. Finn, MD, discussed his ILCA Annual Conference 2023 presentation on optimal frontline treatment in hepatocellular carcinoma and how this standard of care could evolve in the future.
ABM-1310 Lands FDA Fast Track Designation for BRAF V600E+ Glioblastoma
ABM-1310 is an investigational small molecule BRAF inhibitor that is being development for the treatment of various BRAF V600E-mutant solid tumors.
Niraparib Plus Hormone Therapy Improves rPFS in BRCA1/2-Altered mCRPC
Findings from the largest group of patients with BRCA1/2-altered metastatic castration resistant prostate cancer are now available.
Challenges With Adjuvant Therapies in RCC Warrant Further Research
In an interview, Chung-Han Lee, MD, PhD, discussed the challenges, studies, and outcomes previously observed when studying adjuvant treatments for patients with renal cell carcinoma.
FDA Fast Tracks MYTX-011 for Patients with NSCLC and cMET Overexpression
The investigational antibody-drug conjugate, MYTX-011, is one step further in development for the treatment of non–small cel lung cancer with cMET overexpression.
Ontada Names Christine Davis Its New President
Experienced healthcare leader brings 25 years of expertise in real-world data, analytics, and strategic planning.
FDA Okays FTD of IDE161 in BRCA1/2-Mutated Ovarian Cancer
Findings from a phase 1 support the fast track designation given by the FDA to IDE161, a potent, selective, small-molecule inhibitor of PARG, for patients with BRCA1/2 mutant ovarian cancer.
FDA Issues CRL to BLA of OBI Presentation of Pegfilgrastim-cbqv
The FDA has issued a complete response letter for the biologics license application seeking the approval of the on-body injector presentation of pegfilgrastim-cbqv, but has not requested additional findings or clinical trials.
Radioligand Therapy Improves PFS and Responses in SSTR+ Grade 2/3 GEP-NETs
Results from the phase 3 NETTER-2 study will be presented at an upcoming medical conference and shared with drug regulators.
Dosing of Novel DLL3-Targeting Therapy Begins in Patients With SCLC
Following positive phase 1 results, HPN328 treatment in now under evaluation in a phase 1/2 trial.
Defining the Role of Stem Cell Transplant in T-Cell Lymphoma
John Lister, MD, discusses the current role of stem cell transplant in the treatment of T-cell lymphoma, and some of the latest advances in the space.
KRd-D Generates High MRD Negativity Rates in Smoldering Multiple Myeloma
C. Ola Landgren, MD, PhD, discussed the ASCENT trial and his predictions for future developments in the myeloma space.
FDA Grants Orphan Drug Designation to Alisertib in SCLC
A phase 2 study, PUMA-ALI-4201, will further investigate alisertib for the treatment of small cell lung cancer.
FDA Aids IND Application Submission for Ropidoxuridine in Glioblastoma
Responses from the FDA regarding questions submitted for a Type B pre-investigational new drug application meeting have provided a pathway for the start of a phase 2 trial of ropidoxuridine in glioblastoma.
RMC-9805 Hits Milestone in Early-Phase Clinical Trial of KRAS G12D+ Solid Tumors
A new treatment geared to treat the most common driver of RAS-addicted solid tumors has been dosed for the first time in humans.
Moving Forward With Adjuvant Therapies in RCC
Chung-Han Lee, MD, PhD, discusses the types of research that are needed to push forward the development of adjuvant treatments for patients with renal cell carcinoma.
Background on the CARTITUDE-4 Trial of Cilta-Cel in Multiple Myeloma
Binod Dhakal, MD, MS, provides background on the phase 3 CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of patients with lenalidomide-refractory multiple myeloma.
Zeidan Recaps the Phase 3 IMerge Trial of Imetelstat in Lower-Risk MDS
Amer Zeidan, MBBS, discusses the rationale of studying imetelstat in the phase 3 IMerge trial in patients with lower-risk myelodysplastic syndrome.
CheckMate-77T Update: Nivolumab-Based Regimen Improves EFS in NSCLC
In the phase 3 CheckMate-77T trial, a neoadjuvant and adjuvant treatment strategy including nivolumab and chemotherapy improved survival in resectable stage IIA to IIIB non–small cell lung cancer.
2 Clarke Drive Cranbury, NJ 08512